Log In
Print
BCIQ
Print
Print this Print this
 

andexanet alfa (PRT064445, PRT4445)

  Manage Alerts
Collapse Summary General Information
Company Portola Pharmaceuticals Inc.
DescriptionRecombinant protein that reverses the anticoagulant activity of Factor Xa inhibitors
Molecular Target
Mechanism of ActionReverse anticoagulant
Therapeutic ModalityBiologic: Protein
Latest Stage of DevelopmentPhase III
Standard IndicationBleeding
Indication DetailsReverse anticoagulant activity of Factor Xa inhibitors
Regulatory Designation

U.S. - Breakthrough Therapy (Reverse anticoagulant activity of Factor Xa inhibitors);
U.S. - Orphan Drug (Reverse anticoagulant activity of Factor Xa inhibitors)

Partner


 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

5

0

0

0


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone
Get a free BioCentury trial today